A team of researchers from the University of Birmingham has developed a new type of MR contrast agent that combines improved stability with enhanced imaging performance, potentially paving the way for safer diagnostics.

The study, led by professor of bioinorganic chemistry Anna Peacock, focuses on metallo-coiled coils—synthetic, protein-like structures capable of binding gadolinium, the metal typically used in MR contrast agents. Although promising, these structures have historically faced limitations due to their poor chemical stability. To address this, the researchers introduced a covalent cross-linking strategy that reinforces the coiled coils, making them more viable for clinical applications.

Published in the Journal of the American Chemical Society, the work was conducted in collaboration with researchers from the University of Bristol and Università del Piemonte Orientale in Italy, and supported by the U.K.’s Engineering and Physical Sciences Research Council. In a statement summarizing their findings, the researchers describe the agent as a "breakthrough" on the path to better diagnostics.
The cross-linked agent demonstrated a 30% increase in MR relaxivity compared to its non-cross-linked version, suggesting a clearer signal at clinical magnetic field strengths. According to the study, the enhanced design also showed significant improvements in both chemical and biological stability.

“We’ve developed a new class of MR contrast agents that are significantly more efficient than current clinical agents, and we’ve now made them stable,” Peacock said in a statement. “The modular nature of these designs paves the way for safer, smarter imaging in clinical diagnostics.”

The researchers also evaluated the agent in Seronorm, a human serum matrix, to simulate biological conditions. The agent retained its structural integrity and bio-inertness, showing consistent behavior with that seen in aqueous solutions — a key consideration for eventual in vivo use.

The Birmingham, U.K.-based university has filed a patent application for the technology through its tech transfer arm, University of Birmingham Enterprise, and is seeking industry partners for development and commercialization.

The team notes that the approach may also be adapted for broader applications beyond imaging, including catalysis and sensing.

MRI Homepage